前瞻性治疗学报告称，在2025年ESCO大会上，接受[212铅]VMT-a-NET治疗的44%确诊缓解率和87.5%无进展患者

2025-10-20 16:34

Updated interim results with an additional ~19 weeks of follow-up since the prior update
[212Pb]VMT-α-NET continues to be well-tolerated
Objective Response Rate of 44% (7 of 16 patients) in Cohort 2 with SSTR2 expression in all tumors at median follow-up of 41 weeks; 14 of the 16 patients remain free from progression and on study
Initial efficacy data pending for an additional 23 patients in Cohort 2 and 8 patients in Cohort 3, expected during 2026
Perspective will hold a conference call on Monday, October 20, 2025 at 8:30 am ET